

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**MATERNAL CARDIOVASCULAR POTENTIAL AND KINETIC ENERGY INDICES  
IN PRE-ECLAMPTIC AND SMALL-FOR-GESTATIONAL AGE PREGNANCIES**

Juande Gutierrez Henares<sup>1</sup>, Roberto Gutierrez Henares<sup>2</sup>,  
Helen Perry<sup>1</sup>, Asma Khalil<sup>1,3</sup>, Basky Thilaganathan<sup>1,3</sup>

1. Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0RE, UK
2. Electronic engineering, Malaga University, Campus de Teatinos, 29071 Málaga, Spain
3. Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, London SW17 0RE, UK

1

2 **Correspondence to:**

3 Professor Basky Thilaganathan MD, PhD, FRCOG

4 Director of Fetal Medicine Unit

5 Department of Obstetrics and Gynaecology

6 St. George's University Hospitals NHS Foundation Trust

7 Blackshaw Road, London, SW17 0QT, UK.

8 E-Mail: [basky.thilaganathan@nhs.net](mailto:basky.thilaganathan@nhs.net)

9

1 **ABSTRACT**

2

3 **Introduction:** Non-invasive assessment of maternal cardiovascular potential and  
4 kinetic energy can be used to derive the potential to kinetic energy ratio (PKR) and  
5 inotropy index (SMII). The balance of potential to kinetic cardiovascular energy is a  
6 measure of the balance between blood pressure and blood flow. The aim of this study  
7 is to evaluate PKR and SMII in pregnancies complicated by hypertensive disorders  
8 (HDP) and/or small-for-gestational age (SGA) birth.

9 **Methods:** This was a prospective study which enrolled women with singleton  
10 pregnancies between 10 to 41 weeks' gestation. Women with uncomplicated  
11 pregnancies and those who developed HDP and/or SGA were enrolled for  
12 cardiovascular profiling from 20 weeks' gestation. Measurements of the  
13 cardiovascular parameters were performed with a non-imaging ultrasound cardiac  
14 output monitor (USCOM-1A<sup>®</sup>, USCOM Ltd, NSW, Australia).

15 **Results:** A total of 683 women completed the study; 626 controls, 21 with HDP, 19  
16 with SGA and 22 with HDP+SGA. PKR was significantly elevated in placental  
17 dysfunction compared to controls (HDP-alone  $29.81 \pm 9.5$ , HDP+SGA  $44.33 \pm 21.74$ ,  
18 SGA-alone  $31.05 \pm 13.14$ , Controls  $22.30 \pm 7.93$ , all  $p < 0.05$ ). SMII values were only  
19 significantly lower in cases affected by SGA compared to controls (SGA  $1.47 \pm 0.23$   
20  $W/m^2$  vs Controls  $1.75 \pm 0.40 W/m^2$ ,  $p < 0.005$ ). These differences remained statistically  
21 significant even when the analysis was undertaken using MoM values corrected for  
22 gestation.

23 **Conclusions:** The findings of this study suggest that point of care non-invasive  
24 cardiovascular profiling using PKR and SMII may help better delineate pregnancies  
25 affected by specific placental disorders versus those exhibiting health cardiovascular  
26 adaptation to pregnancy. Pregnancies affected by HDP and/or SGA appear to exhibit

1 distinctive profiles in PKR and SMII that reflect low kinetic energy with placental  
2 disorders, but high potential energy in pregnancies affected by HDP.

3

4 **Contributions:** PKR and SMII are novel indices that reflect both cardiovascular and  
5 placentation disorders of pregnancy. They reveal high PKR values in HDP and/or SGA  
6 due to higher PE. SMII is low in SGA-alone cases due to lower kinetic energy.  
7 However, SMII remains unchanged in hypertensive states. Furthermore, the non-  
8 invasive point of care demonstrates the physiological high-flow & low-resistance  
9 adaptation of pregnancy.

10

11 **KEY WORDS:** USCOM, SMII PKR, Pregnancy, Haemodynamics, Potential energy,  
12 Kinetic energy, hypertension, pre-eclampsia, fetal growth restriction

## 1 INTRODUCTION

2

3 The pathogenesis underpinning placental disorders is still not fully understood<sup>1</sup>.  
4 Historically, poor primary placental development has been suggested to be the  
5 physiopathology behind hypertensive disorders of pregnancy (HDP) and small for  
6 gestational age (SGA) birth. Although, poor placentation is implicated in early-onset or  
7 preterm placental disorders, there are some inconsistencies in the medical literature  
8 regarding the placental origins theory<sup>2</sup>. These inconsistencies are particularly  
9 apparent for late onset placental disorders which, in contrast, seem more likely to be  
10 produced by acquired placental dysfunction. The prevailing hypothesis is that the latter  
11 occurs secondary to maternal cardiovascular dysfunction in the face of increased  
12 pregnancy haemodynamic demands with advancing gestation<sup>3-10</sup>. Subsequent  
13 placental hypoperfusion leading to placental dysfunction may then manifest as  
14 hypertensive disorder of pregnancy (HDP) or small-for-gestational age (SGA) birth<sup>11-</sup>  
15 <sup>13</sup>.

16

17 Some researchers have suggested that cardiovascular profiling might help with  
18 screening, diagnosis and management of placental disorders. Non-invasive  
19 continuous wave doppler cardiac output monitoring uses velocity-time integrals (VTIs)  
20 to derive several indices that reflect specific components of haemodynamic function  
21 such as stroke volume, cardiac output, and vascular resistance<sup>14</sup>. When the heart  
22 contracts, it transfers energy to the circulating blood. This energy may be divided in  
23 two types (1) Potential Energy (PE) such as with blood pressure and (2) Kinetic energy  
24 (KE) as for blood flow. The algorithm that integrates the maternal biometric profile and  
25 VTIs can also estimate cardiovascular potential and kinetic energy to derive potential

1 to kinetic energy ratio (PKR) and the inotropy index (SMII)<sup>15</sup>. The balance of potential  
2 to kinetic cardiovascular energy (PKR) is a measure of the balance between blood  
3 pressure and blood flow – possibly a better reflection of composite maternal  
4 myocardial performance than individual haemodynamic indices. The aim of this study  
5 is to evaluate the potential to kinetic energy and inotropy indices in pregnancies  
6 complicated by HDP and/or SGA birth.

7

1 **METHODS**

2

3 *Patients*

4 This was a prospective study which enrolled women with singleton pregnancies  
5 between 10 to 41 weeks' gestation attending a tertiary hospital in Southwest London  
6 between September 2012 and Jun 2017. To establish the reference range for potential  
7 and kinetic energy ratios, women without any pre-existing medical problems at the  
8 time of booking and who did not develop HDP, SGA or other complications in the  
9 pregnancy were recruited. Women who developed HDP and/or SGA were enrolled for  
10 cardiovascular profiling from 20 weeks' gestation. SGA was defined as a neonate  
11 having a birthweight below the 10th centile. Women with HDP were divided into two  
12 groups: those that had an SGA neonate (HDP+SGA) and those with an appropriately  
13 grown neonate (HDP-only). According to the modified ISSHP criteria, those in the  
14 HDP+SGA group had preeclampsia whilst those in the HDP-only group had either  
15 gestational hypertension or preeclampsia. Local research ethics committee approval  
16 (12/LO/0810) was obtained prior to data collection and informed written consent was  
17 obtained from all study participants. All women were examined by their midwives or  
18 obstetricians and both maternal and fetal wellbeing were confirmed prior to  
19 hemodynamic assessment, which was conducted only once per woman. Gestational  
20 age (GA) was calculated from crown–rump length measured at 11 to 13+6 week of  
21 gestation or from head circumference if the woman was more than 14 weeks at first  
22 scan.

23

24

25

1 *Cardiovascular assessment*

2 Measurements of the cardiovascular parameters from the aortic route were performed  
3 in standardised conditions as described in in detail previously<sup>16,17</sup>. In brief, women  
4 were positioned in a semi-recumbent position and a non-imaging probe was used in  
5 the suprasternal notch to obtain VTI to derive indices (USCOM-1A<sup>®</sup> - ultrasound  
6 cardiac output monitor, USCOM Ltd, NSW, Australia). Blood pressure was measured  
7 using Microlife<sup>®</sup> BP 3BTO-A (Microlife Corporation Microlife, Taipei, Taiwan).

8

9 *Statistical analysis*

10 Gestation dependent reference range models were fitted using a weighted cubic  
11 regression curve<sup>18,19</sup>. If normality of the residuals was not assumed, a log<sub>10</sub>  
12 transformation was performed. The mean absolute residuals were then multiplied by  
13  $\sqrt{(\pi/2)}$  and modelled on GA using a weighted curved regression to obtain the  
14 Standard deviation (SD). The 95% reference interval was calculated as mean(GA)  $\pm$   
15  $Z \times SD(GA)$  where  $Z=1.959964$ . The 5<sup>th</sup> and 95<sup>th</sup> centile lines were plotted using  $Z$   
16  $=1.644854$ . The absolute mean residual (50<sup>th</sup> centile) was also use as a reference  
17 value to calculate the multiples of the median (MOM) in HDP and SGA pregnancies.  
18 Homogeneity of proportion between two or more populations was assessed by the chi-  
19 square test<sup>20</sup> ( $X^2$ ). Categorical data were presented as number and percentage, while  
20 continuous data were presented as the median and interquartile range (IQR).  
21 Continuous data were examined using the Shapiro-Wilk test to assess the distribution  
22 of data. Chi-Square test, or Fisher's exact test when appropriate, was used to compare  
23 the categorical variables. Mann Whitney-U test was used to compare the medians of  
24 the hemodynamic variables between the two groups. A p-value less than 0.05 was  
25 deemed statistically significant. The statistical software used were MedCalc<sup>®</sup> V-



- 1 14.8.1(MedCalc Statistical Software, 2014) and SPSS (IBM Corp. Released 2017. IBM
- 2 SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp)
- 3
- 4

## 1 RESULTS

2

3 A total of 683 women completed the study; 626 controls, 21 with HDP, 19 with SGA  
4 and 22 with HDP+SGA. The controls were distributed across all gestations (130 in the  
5 1st trimester, 96 in the 2<sup>nd</sup> trimester and 400 in the 3<sup>rd</sup> trimester). The reference ranges  
6 obtained from the controls for potential to kinetic energy ratio (PKR) and ionotropic  
7 index (SMII) are shown in Figures 1 and 2. The PKR remained between 20-30  
8 throughout gestation with a slight increase towards term, whilst SMII was between 1.6-  
9 1.7 W/m<sup>2</sup> with a slight drop at late term.

10

11 The comparison of demographic variables and cardiovascular indices obtained from  
12 the pregnancies complicated by HDP with or without SGA against gestationally-  
13 matched healthy pregnant women is shown in Table 1. Statistical comparisons with  
14 the 82 gestation-matched controls are shown in Table 2 (Supplemental Tables 1 and  
15 2) and with multiples of the median (MoM) corrected for gestational age in Figures 3  
16 and 4.

17

18 The PKR was significantly elevated in placental dysfunction compared to controls  
19 (HDP-alone 29.81±9.5, HDP+SGA 44.33±21.74, SGA-alone 31.05±13.14, Controls  
20 22.30 ±7.93, all p<0.05). These differences remained statistically significant even  
21 when the analysis was undertaken using MoM values corrected for gestation (Figure  
22 3). SMII values were only significantly lower in cases affected by SGA compared to  
23 controls (SGA 1.47 ±0.23 W/m<sup>2</sup> vs Controls 1.75 ±0.40 W/m<sup>2</sup>, p<0.005), and this  
24 finding persisted with MoM-based analysis.

25

# 1 DISCUSSION

2

## 3 *Summary of main results*

4 The findings of this study demonstrate stable maternal cardiovascular function with a  
5 stable ionotropy index (SMII) throughout normal pregnancy accompanied by a slight  
6 increase in potential to kinetic ratio (PKR) near term. HDP and/or SGA is universally  
7 associated with significantly reduced kinetic energy compared to controls. HDP with  
8 SGA is associated with a significant rise in PKR due to an increase in potential energy,  
9 whilst SGA demonstrates low SMII due to decreased kinetic energy.

10

## 11 *Interpretation of study findings and comparison with published literature*

12 The potential to kinetic energy ratio (PKR) reflects the balance in between blood  
13 pressure and blood flow. In healthy adults, the normal ratio is around 30 (30 to 1)<sup>14</sup>,  
14 and it appears unchanged in pregnancy except for a slight rise near term. As PKR is  
15 a dimensionless ratio, like blood pressure, it does not need to be corrected for maternal  
16 characteristics such as height and weight. Similarly, the inotropic index (SMII), is the  
17 sum of the potential and kinetic energies produced by cardiac contraction (inotropy) -  
18 corrected by the body surface area (BSA) to make results comparable. The finding of  
19 low kinetic energy – equivalent to poor blood flow and impaired perfusion - in both  
20 HDP and SGA pregnancies is consistent with previous echocardiographic studies  
21 demonstrating impaired cardiovascular function in both disorders<sup>4,5,7</sup>. Within the  
22 pathological pregnancies (HDP±SGA), potential energy (and PKR) is higher in HDP  
23 and lower in SGA. Elevated PKR is consistent with a maternal low flow and high  
24 resistance state in these pathological pregnancies as typically occurs un hypertension.

1 Kinetic energy (and SMII) is lower in SGA pregnancies consistent with poorer cardiac  
2 contractility in SGA cases, which has been previously reported<sup>21-23</sup>. Valensise *et al.*<sup>21</sup>,  
3 reported lower contractility (SMII 1.40  $W/m^2$ ) was associated to lower birthweight  
4 babies – findings which were confirmed in two similar studies<sup>22,23</sup>.

5

### 6 *Clinical and research Implications*

7 HDP and/or SGA present with characteristic patterns of PE, KE, PKR and SMII  
8 haemodynamic profiles which may be ascertained by a relatively cheap point-of-care  
9 instrument that requires very little training - unlike echocardiography. Assessment of  
10 PE and KE in at-risk pregnancies may be of clinical value in distinguishing pathological  
11 from normal pregnancies, as HDP pregnancies typically demonstrate high PKR and  
12 SGA pregnancies exhibit low SMII compared to controls. Prospective and blinded  
13 studies will be required to establish the clinical value of this point-of-care tool in  
14 effective medical triage and the impact on maternal and neonatal outcomes. The study  
15 findings also support the hypothesis that maternal cardiovascular impairment is a  
16 consistent finding in both HDP and SGA – traditionally considered to be ‘placental’  
17 disorders. Normal pregnancy is associated with stable PKR and SMII haemodynamic  
18 indices throughout pregnancy, whereas HDP pregnancies are characterised by  
19 increased PKR/potential energy and SGA associated with reduced SMII/kinetic energy  
20 due to reduced cardiac contractility.

21

### 22 *Strengths and limitations*

23 The main strengths of our study are the prospective assessment of a large cohort of  
24 pregnancies with HDP and SGA as well as control pregnancies. Furthermore, in case

1 variables could be affected by gestational age, we used gestation matched controls  
2 and device-specific reference ranges. One limitation of the study is that as many  
3 cardiovascular indices, there is the potential for PKR and SMII to vary with body  
4 morphology, but the use of ratios should have minimised this effect. Furthermore, the  
5 indices studies are obtained from a peripheral waveform and the repeatability and  
6 reproducibility of these indices need to be established before screening studies are  
7 undertaken to establish their clinical utility.

8

## 9 **CONCLUSIONS**

10 The findings of this study suggest that point of care non-invasive cardiovascular  
11 profiling using PKR and SMII may be helpful in distinguishing pregnancies affected by  
12 specific placental disorders versus those exhibiting healthy cardiovascular adaptation  
13 to pregnancy. Pregnancies affected by HDP and/or SGA appear to exhibit distinctive  
14 profiles in PKR and SMII that reflect low kinetic energy with placental disorders, but  
15 high potential energy in pregnancies affected by HDP. These findings support the  
16 hypothesis of impaired maternal cardiovascular function in the pathogenesis of both  
17 HDP and SGA, but the sensitivity and specificity of PKR and SMII for these  
18 uteroplacental disorders still to be established.

19

## 1 REFERENCES

2

- 3 1. Falco ML, Sivanathan J, Laoreti A, Thilaganathan B, Khalil A. Placental  
4 histopathology associated with pre-eclampsia: systematic review and meta-  
5 analysis. *Ultrasound Obstet Gynecol* 2017; 50: 295–301.
- 6 2. Melchiorre K, Giorgione V, Thilaganathan B. The placenta and preeclampsia:  
7 villain or victim? *Am. J. Obstet. Gynecol.* 2021; 0. doi:  
8 10.1016/j.ajog.2020.10.024
- 9 3. Verlohren S, Perschel FH, Thilaganathan B, Dröge LA, Henrich W, Busjahn A,  
10 Khalil A. Angiogenic Markers and Cardiovascular Indices in the Prediction of  
11 Hypertensive Disorders of Pregnancy. *Hypertension* 2017; 69: 1192–7.
- 12 4. Melchiorre K, Sutherland G, Baltabaeva A, Liberati M, Thilaganathan B.  
13 Impaired mid-gestational maternal cardiac function and left ventricular  
14 remodelling in women who subsequently develop preterm but not term  
15 preeclampsia. *Pregnancy Hypertens* 2011; 1: 263–4.
- 16 5. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B.  
17 Maternal cardiac dysfunction and remodeling in women with preeclampsia at  
18 term. *Hypertension* 2011; 57: 85–93.
- 19 6. Vinayagam D, Gutierrez J, Binder J, Mantovani E, Thilaganathan B, Khalil A.  
20 Impaired maternal hemodynamics in morbidly obese women: a case–control  
21 study. *Ultrasound Obstet Gynecol* 2017; 50: 761–5.
- 22 7. Buddeberg BS, Sharma R, O’Driscoll JM, Kaelin Agten A, Khalil A,  
23 Thilaganathan B. Cardiac maladaptation in term pregnancies with  
24 preeclampsia. *Pregnancy Hypertens* 2018; 13: 198–203.
- 25 8. Melchiorre K, Sharma R, Thilaganathan B. Cardiovascular implications in  
26 preeclampsia: An overview. *Circulation* 2014; 130: 703–14.
- 27 9. Borges VTM, Zanati SG, Peracoli MTS, Poiati JR, Romao-Veiga M, Peracoli  
28 JC, Thilaganathan B. Maternal left ventricular hypertrophy and diastolic  
29 dysfunction and brain natriuretic peptide concentration in early- and late-onset  
30 pre-eclampsia. *Ultrasound Obstet Gynecol* 2018; 51: 519–23.
- 31 10. Thilaganathan B, Kalafat E. Cardiovascular system in preeclampsia and  
32 beyond. *Hypertension* 2019; 73: 522–31.
- 33 11. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG,

- 1 Brown MA. The classification, diagnosis and management of the hypertensive  
2 disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy*  
3 *Hypertens* 2014; 4: 97–104.
- 4 12. Perry H, Gutierrez J, Binder J, Thilaganathan B, Khalil A. Maternal arterial  
5 stiffness in hypertensive pregnancies with and without a small-for-gestational-  
6 age neonate. *Ultrasound Obstet Gynecol* 2019 Oct 15; 0. doi:  
7 10.1002/uog.21893
- 8 13. Perry H, Khalil A, Thilaganathan B. Preeclampsia and the cardiovascular  
9 system: An update. *Trends Cardiovasc Med* 2018; 0: 1–9.
- 10 14. Madigan VM, Smith BE. Non-invasive method for rapid bedside estimation of  
11 inotropy: Theory and preliminary clinical validation. *Br J Anaesth* 2013; 111:  
12 580–8.
- 13 15. Wood AW. *Physiology, Biophysics, and Biomedical Engineering*. CRC Press,  
14 2016. .
- 15 16. Vinayagam D, Thilaganathan B, Stirrup O, Mantovani E, Khalil A. Maternal  
16 hemodynamics in normal pregnancy: reference ranges and role of maternal  
17 characteristics. *Ultrasound Obstet Gynecol* 2018; 51: 665–71.
- 18 17. Perry H, Stirrup O, Gutierrez J, Vinayagam D, Thilaganathan B, Khalil A.  
19 Influence of maternal characteristics and gestational age on haemodynamic  
20 indices: NICOM device-specific reference ranges. *Ultrasound Obstet Gynecol*  
21 2018. doi: 10.1002/uog.20179
- 22 18. Altman DG. Construction of age-related reference centiles using absolute  
23 residuals. *Stat Med* 1993; 12: 917–24.
- 24 19. Altman DG, Chitty LS. Design and analysis of studies to derive charts of fetal  
25 size. *Ultrasound Obstet. Gynecol.* 1993; 3: 378–84.
- 26 20. Open Learning Initiative. Test of Homogeneity [Internet]. Lumen, concepts Stat.  
27 2018 [cited 2018 Oct 11]. Available from:  
28 [https://courses.lumenlearning.com/wmopen-concepts-statistics/chapter/test-of-](https://courses.lumenlearning.com/wmopen-concepts-statistics/chapter/test-of-homogeneity/)  
29 [homogeneity/](https://courses.lumenlearning.com/wmopen-concepts-statistics/chapter/test-of-homogeneity/)
- 30 21. Valensise H, Farsetti D, Lo Presti D, Pisani I, Tiralongo GM, Gagliardi G,  
31 Vasapollo B, Novelli GP. Preterm delivery and elevated maternal total vascular  
32 resistance: signs of suboptimal cardiovascular adaptation to  
33 pregnancy? *Ultrasound Obstet Gynecol* 2016; 48: 491–5.
- 34 22. Tiralongo GM, Lo Presti D, Pisani I, Gagliardi G, Scala RL, Novelli GP,

- 1 Vasapollo B, Andreoli A, Valensise H. Assessment of total vascular resistance  
2 and total body water in normotensive women during the first trimester of  
3 pregnancy. A key for the prevention of preeclampsia. *Pregnancy Hypertens*  
4 2015; 5: 193–7.
- 5 23. Gagliardi G, Tiralongo GM, Lo Presti D, Pisani I, Farsetti D, Vasapollo B,  
6 Novelli GP, Andreoli A, Valensise H. D2. Screening of preeclampsia (PE) in  
7 the first trimester: high total vascular resistance (TVR) with a reduced fat mass  
8 increase the risk in normo BMI patients. *J Matern Neonatal Med* 2016; 29: 17–  
9 17.
- 10



**Table 1:** Maternal characteristics and pregnancy outcome for the study population. Data provided as mean (standard deviation).

	<b>Controls (n=82)</b>	<b>HDP-alone (n=21)</b>	<b>HDP and SGA (n=22)</b>	<b>SGA-alone (n=19)</b>
<b>Maternal characteristics</b>				
Age (yrs)	32.37 (5.70)	31.75 (6.36)	31.93 (4.15)	31.58 (6.62)
Height (m)	1.63 (0.06)	1.62 (0.07)	1.60 (0.07)	1.60 (0.07)
Weight (Kg)	75.38 (2.63)	85.05 (15.47)	83.99 (14.62)	73.85 (14.02)
BMI (Kg/m <sup>2</sup> )	28.02 (4.34)	32.42 (7.28)	32.72 (6.16)	28.79 (5.28)
BSA (m <sup>2</sup> )	1.88 (0.18)	2.02 (0.21)	2.00 (0.22)	1.84 (0.20)
GA at measurement (wks)	27.21 (1.32)	26.27 (2.12)	26.27 (1.89)	27.03 (1.66)
<b>Ethnicity</b>				
Caucasian	61.0%	52.4%	36.3%	26.3%
Afro-Caribbean	18.3%	14.3%	31.8%	15.8%
Asian	17.1%	23.8%	27.3%	57.9%
Other	3.6%	9.5%	4.6%	0%
<b>Pregnancy outcomes</b>				
GA at birth (wks)	39.18 (4.51)	36.78 (5.42)	31.41 (5.39)	36.67 (4.17)
Birth weight (g)	3333.8 (684.1)	2644.2 (829.3)	1300.7 (764.1)	2195.7 (696.8)

**Table 2:** Maternal cardiovascular profiles in the various study groups. Data given as mean (SD). Symbols indicate statistical significance from: Control (†), HDP-alone (\*), HDP+SGA (#) or SGA-alone (\$)

	Control (n=82)	HDP alone (n=21)	HDP+SGA (n=22)	SGA alone (n=19)
<b>Measured CV indices</b>				
MAP (mmHg)	85.11 (7.64) <sup>*#</sup>	99.69 (13.85) <sup>†#</sup>	111.28 (13.30) <sup>†*\$</sup>	87.12 (8.82) <sup>*#</sup>
HR (bpm)	82.84 (13.17)	82.20 (9.80)	80.12 (17.66)	85.21 (15.04)
SV (ml)	86.38 (16.96) <sup>#</sup>	83.65 (18.35) <sup>#</sup>	69.37 (19.36) <sup>†*</sup>	72.83 (15.42) <sup>†</sup>
<b>Calculated CV indices</b>				
SVI (ml)	46.20 (9.50) <sup>#</sup>	41.73 (9.72) <sup>#</sup>	34.97 (9.12) <sup>†*</sup>	39.62 (8.13) <sup>†</sup>
CO (L/min)	7.08 (1.50) <sup>#</sup>	6.81 (1.48) <sup>#</sup>	5.42 (1.10) <sup>†*</sup>	6.05 (0.94) <sup>†</sup>
CI (L/min/m <sup>2</sup> )	3.78 (0.83) <sup>#</sup>	3.39 (0.73) <sup>#</sup>	2.74 (0.54) <sup>†*\$</sup>	3.29 (0.49) <sup>†#</sup>
TPR (dyn·s/cm <sup>5</sup> /m <sup>2</sup> )	1012.64 (227.04) <sup>*#</sup>	1229.90 (295.44) <sup>†#</sup>	1709.57 (520.71) <sup>†*\$</sup>	1187.15 (246.92) <sup>†#</sup>
TPRI (dyn·s/cm <sup>5</sup> /m <sup>2</sup> )	1900.35 (443.08) <sup>*#</sup>	2476.80 (608.54) <sup>†#</sup>	3360.76 (869.36) <sup>†*\$</sup>	2187.56 (515.29) <sup>†#</sup>
<b>Novel CV indices</b>				
PE (mJ)	980.31 (215.27) <sup>*#</sup>	1104.70 (250.19) <sup>†</sup>	1086.87 (398.29) <sup>\$</sup>	837.30 (151.25) <sup>†**</sup>
KE (mJ)	52.18 (30.17) <sup>#</sup>	43.10 (21.74)	36.82 (40.61) <sup>†</sup>	31.97 (15.63) <sup>†</sup>
PKR	22.30 (7.93) <sup>*#</sup>	29.81 (9.5) <sup>†#</sup>	44.33 (24.27) <sup>†*</sup>	31.05 (13.14) <sup>†</sup>
SMII (W/m <sup>2</sup> )	1.75 (0.40) <sup>\$</sup>	1.77 (0.41) <sup>\$</sup>	1.72 (0.48) <sup>\$</sup>	1.47 (0.23) <sup>†**</sup>


**Supplemental Table 1:** Statistical comparisons of measured variables between various study groups \* denotes statistical significance (P<0.05)

	HDP-alone vs Controls	HDP-SGA vs Controls	SGA-alone Vs Controls	HDP-Alone vs HDP-SGA	HDP-Alone Vs SGA-alone	HDP-SGA vs SGA-Alone
<b>Measured CV indices</b>						
<i>MAP</i>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	0.319	<b>0.010*</b>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>
<i>HR</i>	0.835	0.674	0.492	0.671	0.453	0.357
<i>SV</i>	0.519	<b>&lt;0.001*</b>	<b>0.001*</b>	<b>0.030*</b>	0.052	0.728
<b>Calculated CV indices</b>						
<i>SVI</i>	0.058	<b>&lt;0.001*</b>	<b>0.006*</b>	<b>0.038*</b>	0.465	0.143
<i>CO</i>	0.479	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	<b>0.002*</b>	0.057	0.101
<i>CI</i>	0.050	<b>&lt;0.001*</b>	<b>0.001*</b>	<b>0.004*</b>	0.627	<b>0.003*</b>
<i>TPR</i>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	<b>0.003*</b>	<b>&lt;0.001*</b>	0.624	<b>&lt;0.001*</b>
<i>TPRI</i>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	<b>0.015*</b>	<b>&lt;0.001*</b>	0.115	<b>&lt;0.001*</b>
<b>Novel CV indices</b>						
<i>PE</i>	<b>0.046*</b>	0.095	<b>0.007*</b>	0.806	<b>&lt;0.001*</b>	<b>0.014*</b>
<i>KE</i>	0.188	<b>&lt;0.001*</b>	<b>0.002*</b>	0.058	<b>0.022*</b>	0.601
<i>PKR</i>	<b>0.003*</b>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	<b>0.016*</b>	0.790	<b>0.010*</b>
<i>SMII</i>	0.700	0.824	0.005*	0.725	<b>0.009*</b>	<b>0.037*</b>


**Supplemental Table 2:** Statistical comparisons of measured variables between groups Bonferroni corrected. \* denotes statistical significance (P<0.05)

	HDP-alone vs Controls	HDP-SGA vs Controls	SGA-alone Vs Controls	HDP-Alone vs HDP-SGA	HDP-Alone Vs SGA-alone	HDP-SGA vs SGA-Alone
<b>Measured CV indices</b>						
<i>MAP</i>	<b>&lt;0.001*</b>	<b>&lt;0.001*</b>	1.000	<b>0.006*</b>	<b>0.001*</b>	<b>&lt;0.001*</b>
<i>HR</i>	1.000	1.000	1.000	1.000	1.000	1.000
<i>SV</i>	1.000	<b>&lt;0.001*</b>	<b>0.016*</b>	<b>0.181*</b>	0.312	1.000
<b>Calculated CV indices</b>						
<i>SVI</i>	0.348	<b>&lt;0.001*</b>	<b>0.036*</b>	0.228	1.000	0.858
<i>CO</i>	1.000	<b>&lt;0.001*</b>	<b>0.026*</b>	<b>0.012*</b>	0.342	0.606
<i>CI</i>	0.301	<b>&lt;0.001*</b>	<b>0.006*</b>	0.027	1.000	0.076
<i>TPR</i>	<b>0.020*</b>	<b>&lt;0.001*</b>	0.096	<b>0.024*</b>	1.000	<b>0.018*</b>
<i>TPRI</i>	<b>0.001*</b>	<b>0.001*</b>	0.091	<b>0.001*</b>	0.690	<b>0.001*</b>
<b>Novel CV indices</b>						
<i>PE</i>	0.276	0.571	<b>0.042*</b>	1.000	<b>0.001*</b>	0.084
<i>KE</i>	1.000	<b>0.001*</b>	<b>0.012*</b>	0.348	0.132	1.000
<i>PKR</i>	<b>0.018*</b>	<b>&lt;0.001*</b>	<b>0.001*</b>	0.096	1.000	0.061
<i>SMII</i>	1.000	1.000	<b>0.015*</b>	1.000	0.054	0.222


**Figure 1:** Scatterplot showing reference range for the potential to kinetic energy ratio (PKR) with gestational age in 626 women with an uncomplicated singleton pregnancy. Median (50th centile) shown as a solid line with 5th and 95th centiles shown as dotted lines.



**Figure 2:** Scatterplot showing reference range for the inotropic Index (SMII) with gestational age in 626 women with an uncomplicated singleton pregnancy. Median (50th centile) shown as a solid line with 5th and 95th centiles shown as dotted lines.



**Figure 3:** Box-plots showing the potential to kinetic energy ratio as multiples of the median (MoM) of the expected value for gestation in the three different phenotypes for uteroplacental dysfunction. Data shown as Median and interquartile range in the box.



**Figure 4:** Box-plots showing the ionotropic index (SMII) as multiples of the median (MoM) of the expected value for gestation in the three different phenotypes for uteroplacental dysfunction. Data shown as Median and interquartile range in the box.

